DI Mobile Menu

Search form


Nuclear Imaging

Nuclear Imaging

Amyloid imaging, used to detect plaques in the brain, may help diagnose cardiac amyloidosis, researchers said.

Combining fluorodeoxyglucose-PET, MRI and cerebrospinal analysis significantly increases the accuracy of predicting Alzheimer’s disease progression.

F-18-flurorothymidine PET appears to be useful in assessing the grade and proliferation in gliomas, especially in newly diagnosed patients.

Dose awareness extends to nuclear medicine exams with the development of online materials to guide providers on radiopharmaceutical dose utilization.

Video: Roberto Soto, MD, discusses using PET imaging with Amyvid for Alzheimer’s evaluation, including reimbursement, training, and benefits of the new test.

Video: Roberto Soto, MD, of Precision Imaging, shows a recent PET imaging case using Amyvid, recently approved for evaluation of Alzheimer's.

Clinicians at Mount Sinai in New York are the first in the state to use a recently FDA-approved PET technique with florbetapir to detect Alzheimer’s disease.


Subscribe to Nuclear Imaging on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.